Nelson Santiago Vispo

Dr. Nelson Santiago Vispo

Bionatura Journal, Clinical biotec, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Marjorie ZamboninoMarjorie Zambonino
Marjorie Zambonino
EQErnesto Mateo Quizhpe
Ernesto Mateo Quizhpe
Francisco JaramilloFrancisco Jaramillo
Francisco Jaramillo
Ashiqur RahmanAshiqur Rahman
Ashiqur Rahman
Nelson Santiago VispoNelson Santiago Vispo
Nelson Santiago Vispo
Si Amar DahoumaneSi Amar Dahoumane
Si Amar Dahoumane
The synthesis and assembly of nanoparticles using green technology has been an excellent option in nanotechnology because they are easy to implement, cost-efficient, eco-friendly, risk-free, and amenable to scaling up. They also do not require sophisticated equipment nor well-trained professionals. Bionanotechnology involves various biological systems as suitable nanofactories, including biomolecules, bacteria, fungi, yeasts, and plants. Biologically inspired nanomaterial fabrication approaches have shown great potential to interconnect microbial or plant extract biotechnology and nanotechnology. The present article extensively reviews the eco-friendly production of metalloid nanoparticles, namely made of selenium (SeNPs) and tellurium (TeNPs), using various microorganisms, such as bacteria and fungi, and plants’ extracts. It also discusses the methodologies followed by materials scientists and highlights the impact of the experimental sets on the outcomes and shed light on the underlying mechanisms. Moreover, it features the unique properties displayed by these biogenic nanoparticles for a large range of emerging applications in medicine, agriculture, bioengineering, and bioremediation.

1 October 2004 in Cancer Research
Verified
Journal Article
Open access
PDF file
SPSilvio E. Perea
Silvio E. Perea
OROsvaldo Reyes
Osvaldo Reyes
YIYaquelin Puchades Izaguirre
Yaquelin Puchades Izaguirre
OMOsmani Mendoza
Osmani Mendoza
Nelson Santiago VispoNelson Santiago Vispo
Nelson Santiago Vispo
DADaniel F. Alonso
Daniel F. Alonso
Protein Kinase (casein kinase 2, CK2) is a serine-threonine kinase that is frequently dysregulated in many human tumors. Therefore we hypothesized that peptides capable of binding to the CK2 acidic domain may exhibit potential anticancer properties. By screening a random cyclic peptide phage display library, we have identified a novel peptide, P15, that abrogated CK2 phosphorylation by blocking the substrate in vitro. To verify its potential antineoplastic effect, P15 was fused to the cell-penetrating peptide derived from the HIV-Tat protein. Interestingly, P15-Tat induced apoptosis as evidenced by rapid caspase activation and cellular cytotoxicity in a variety of tumor cell lines. Furthermore, direct injection of P15-Tat into C57BL6 mice bearing day 7-established solid tumors, resulted in substantial regression of the tumor mass. Our findings describe a new proapoptotic cyclic peptide that blocks the CK2 phosphorylation and exhibits antitumor effect in vivo, indicating that the P15 peptide may potentially be used clinically to treat solid tumors or as an adjuvant for cancer therapy.

21 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TRThelvia Isabel Ramos
Thelvia Isabel Ramos
CVCarlos Villacís
Carlos Villacís
Katherine V. López-AguilarKatherine V. López-Aguilar
Katherine V. López-Aguilar
LPLeandro Santiago Padilla
Leandro Santiago Padilla
CAClaudia Altamirano
Claudia Altamirano
Nelson Santiago VispoNelson Santiago Vispo
Nelson Santiago Vispo
Nanomedicine plays an essential role in developing new therapies through novel drug delivery systems, diagnostic and imaging systems, vaccine development, antibacterial tools, and high-throughput screening. One of the most promising drug delivery systems are nanoparticles, which can be designed with various compositions, sizes, shapes, and surface modifications. These nanosystems have improved therapeutic profiles, increased bioavailability, and reduced the toxicity of the product they carry. However, the clinical translation of nanomedicines requires a thorough understanding of their properties to avoid problems with the most questioned aspect of nanosystems: safety. The particular physicochemical properties of nano-drugs lead to the need for additional safety, quality, and efficacy testing. Consequently, challenges arise during the physicochemical characterization, the production process, in vitro characterization, in vivo characterization, and the clinical stages of development of these biopharmaceuticals. The lack of a specific regulatory framework for nanoformulations has caused significant gaps in the requirements needed to be successful during their approval, especially with tests that demonstrate their safety and efficacy. Researchers face many difficulties in establishing evidence to extrapolate results from one level of development to another, for example, from an in vitro demonstration phase to an in vivo demonstration phase. Additional guidance is required to cover the particularities of this type of product, as some challenges in the regulatory framework do not allow for an accurate assessment of NPs with sufficient evidence of clinical success. This work aims to identify current regulatory issues during the implementation of nanoparticle assays and describe the major challenges that researchers have faced when exposing a new formulation. We further reflect on the current regulatory standards required for the approval of these biopharmaceuticals and the requirements demanded by the regulatory agencies. Our work will provide helpful information to improve the success of nanomedicines by compiling the challenges described in the literature that support the development of this novel encapsulation system. We propose a step-by-step approach through the different stages of the development of nanoformulations, from their design to the clinical stage, exemplifying the different challenges and the measures taken by the regulatory agencies to respond to these challenges.

26 May 2022 in Frontiers in Chemistry
Verified
Journal Article
Open access
AEAlexis Eras
Alexis Eras
DCDanna Castillo
Danna Castillo
MSMargarita Suárez
Margarita Suárez
Nelson Santiago VispoNelson Santiago Vispo
Nelson Santiago Vispo
Fernando AlbericioFernando Albericio
Fernando Albericio
Hortensia RodriguezHortensia Rodriguez
Hortensia Rodriguez
Cancer is one of the diseases with the highest mortality rate. Treatments to mitigate cancer are usually so intense and invasive that they weaken the patient to cure as dangerous as the own disease. From some time ago until today, to reduce resistance generated by the constant administration of the drug and improve its pharmacokinetics, scientists have been developing drug delivery system (DDS) technology. DDS platforms aim to maximize the drugs’ effectiveness by directing them to reach the affected area by the disease and, therefore, reduce the potential side effects. Erythrocytes, antibodies, and nanoparticles have been used as carriers. Eleven antibody–drug conjugates (ADCs) involving covalent linkage has been commercialized as a promising cancer treatment in the last years. This review describes the general features and applications of DDS focused on the covalent conjugation system that binds the antibody carrier to the cytotoxic drug.

2 August 2022 in Marine Drugs
Verified
Journal Article
Open access
PDF file
JSJuan Pablo Saucedo
Juan Pablo Saucedo
ELEdison Fernando Gushque Lamiña
Edison Fernando Gushque Lamiña
Nelson Santiago VispoNelson Santiago Vispo
Nelson Santiago Vispo
Jenny Rodriguez LeónJenny Rodriguez León
Jenny Rodriguez León
MGMarco Esteban Gudiño Gomezjurado
Marco Esteban Gudiño Gomezjurado
Frank AlexisFrank Alexis
Frank Alexis
Peptide therapeutics play a key role in the development of new medical treatments. The traditional focus on endogenous peptides has shifted from first discovering other natural sources of these molecules, to later synthesizing those with unique bioactivities. This review provides concise information concerning antimicrobial peptides derived from marine crustaceans for the development of new therapeutics. Marine arthropods do not have an adaptive immune system, and therefore, they depend on the innate immune system to eliminate pathogens. In this context, antimicrobial peptides (AMPs) with unique characteristics are a pivotal part of the defense systems of these organisms. This review covers topics such as the diversity and distribution of peptides in marine arthropods (crustacea and chelicerata), with a focus on penaeid shrimps. The following aspects are covered: the defense system; classes of AMPs; molecular characteristics of AMPs; AMP synthesis; the role of penaeidins, anti-lipopolysaccharide factors, crustins, and stylicins against microorganisms; and the use of AMPs as therapeutic drugs. This review seeks to provide a useful compilation of the most recent information regarding AMPs from marine crustaceans, and describes the future potential applications of these molecules.

18 December 2020 in Polymers
Verified
Journal Article
Open access
PDF file
Maria RomeroMaria Romero
Maria Romero
LSLilian Spencer
Lilian Spencer
Nelson Santiago VispoNelson Santiago Vispo
Nelson Santiago Vispo
Karla VizueteKarla Vizuete
Karla Vizuete
Alexis DebutAlexis Debut
Alexis Debut
Frank AlexisFrank Alexis
Frank Alexis
Suture biomaterials are critical in wound repair by providing support to the healing of different tissues including vascular surgery, hemostasis, and plastic surgery. Important properties of a suture material include physical properties, handling characteristics, and biological response for successful performance. However, bacteria can bind to sutures and become a source of infection. For this reason, there is a need for new biomaterials for suture with antifouling properties. Here we report two types of cellulose fibers from coconut (Cocos nucifera) and sisal (Agave sisalana), which were purified with a chemical method, characterized, and tested in vitro and in vivo. According to SEM images, the cellulose fiber from coconut has a porous surface, and sisal has a uniform structure without internal spaces. It was found that the cellulose fiber from sisal has mechanical properties closer to silk fiber biomaterial using Ultimate Tensile Strength. When evaluating the cellulose fibers biodegradability, the cellulose from coconut showed a rapid weight loss compared to sisal. The antifouling test was negative, which demonstrated that neither possesses intrinsic microbicidal activity. Yet, a weak biofilm was formed on sisal cellulose fibers suggesting it possesses antifouling properties compared to cellulose from coconut. In vivo experiments using healthy mice demonstrated that the scarring and mechanical connection was like silk for both cellulose fibers. Overall, our results showed the potential use of cellulose fibers from vegetal for surgical sutures due to excellent mechanical properties, rapid degradation, and no bacterial adhesion.